SINTX Technologies Inc

Análisis de la acción SINTX Technologies Inc (SINT)

$1.530

+0.031 (+2.00%)Al cierre

Loading chart…
High
1.560
Open
1.500
VWAP
1.53
Vol
33.59K
Mkt Cap
3.17M
Low
1.500
Amount
51.39K
EV/EBITDA, TTM
-0.28

SINTX Technologies, Inc. is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. It is engaged in the research, development, and manufacturing of silicon nitride. Its core business includes biomedical applications and antipathogenic applications. It has been focused on medical grade silicon nitride. Spinal implants made from its silicon nitride have been implanted in humans. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. Its composition of silicon nitride antipathogenic powder may enable manufacturing surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. It manufactures advanced ceramic powders and components in its manufacturing facilities based in Salt Lake City, Utah.

sintx.com

AI analysis of SINTX Technologies Inc (SINT)

hold

SINTX Technologies Inc is currently not a good buy due to its low price of $1.50, which is significantly below its analyst price targets of $6 and $10. However, the stock has a low RSI of 35.04, indicating it may be oversold. The main risk is its substantial year-to-date decline of 60.32%, suggesting ongoing challenges.

Métricas de valoración

The current forward P/E ratio for SINTX Technologies Inc (SINT) is 0.00, compared to its 5-year average forward P/E of -18.68.

Forward P/E

Fair
5Y Average P/E
-18.68
Current P/E
0.00
Sobrevalorada
58.40
Infravalorada
-95.75

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-0.36
Current EV/EBITDA
-0.28
Sobrevalorada
0.29
Infravalorada
-1.01

Forward P/S

Fair
5Y Average P/S
4.86
Current P/S
1.89
Sobrevalorada
9.97
Infravalorada
-0.24

Alphio AI Price Scenarios for SINT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%SINT

$2.63

Precio del escenario

B

Base

Base · 50%SINT

$1.91

Precio del escenario

B

Bear

Bear · 25%SINT

$1.46

Precio del escenario

Cronología de eventos

2026-08-13 (ET)

06:30:00

Selling Stockholders Plan to Sell 1.27M Shares of Common Stock

2026-06-25 (ET)

06:30:00

Sintx Technologies Files to Sell 5.82M Shares of Common Stock

2026-06-22 (ET)

10:00:00

Sintx Technologies Secures Over $3.2M in Orders

2026-03-19 (ET)

07:50:00

SINTX Completes First-in-Human Surgery, Enters Global Orthopedic Market

2026-02-18 (ET)

08:40:00

Sintx Technologies Appoints Ryan Elmore as President

Noticias

SINT FAQ — answered by Alphio AI

SINTX Technologies, Inc. is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. It is engaged in the research, development, and manufacturing of silicon nitride. Its core business includes biomedical applications and antipathogenic applications. It has been focused on medical grade silicon nitride. Spinal implants made from its silicon nitride have been implanted in humans. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. Its composition of silicon nitride antipathogenic powder may enable manufacturing surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. It manufactures advanced ceramic powders and components in its manufacturing facilities based in Salt Lake City, Utah. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

SINTX Technologies Inc is currently not a good buy due to its low price of $1.50, which is significantly below its analyst price targets of $6 and $10. However, the stock has a low RSI of 35.04, indicating it may be oversold. The main risk is its substantial year-to-date decline of 60.32%, suggesting ongoing challenges.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis